Gene therapy company Affinia Therapeutics has closed a $110 million Series B financing. Affinia Therapeutics will use the proceeds to further develop its proprietary gene therapy platform, advance programs into the clinic, and for general corporate purposes. “Since founding the company, we have had the interest of leading biotech investors as well as strategic partners […]

Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture and commercialize CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CTX001 represents the first potential treatment to emerge from the joint research program initiated in […]

Adagio Therapeutics has completed a $336 million Series C financing that will support continued advancement of ADG20, Adagio’s lead clinical candidate being developed as a single agent for both the treatment and prevention of COVID-19, as well as potential future coronaviruses. ADG20 is a monoclonal antibody distinguished from other antibody treatments targeting the COVID-19 by […]

Precision cancer medicine company Tango Therapeutics has entered into a definitive merger agreement with SPAC (special purpose acquisition company) BCTG Acquisition Corp. In addition to the approximately $167 million contributed by BCTG, a group of healthcare investors has committed to participate in the transaction through a common stock PIPE (or private investment in public equity) […]